Acquired aplastic anemia is a rare and serious blood disorder characterized by a deficiency of blood cells in the bone marrow. While there may not be specific companies exclusively focused on acquired aplastic anemia, various pharmaceutical and biotechnology companies may be involved in the development, manufacturing, and distribution of medications and therapies used in the treatment of bone marrow disorders and related conditions.
Novartis receives FDA approval for Cosentyx® (secukinumab) for treating moderate-to-severe AA in adults who have failed previous immunosuppressive therapy.
Apellis Pharmaceuticals introduces APL-2 (pegcetacoplan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a condition often associated with AA, offering a potential new therapy option.
Regen Biopharma presents promising data from a Phase 2 clinical trial of REGN410, a novel immunosuppressive drug, demonstrating positive early results in AA patients
The Aplastic Anemia & MDS International Foundation (AA&MDSIF) partners with pharmaceutical companies and research institutions to fund clinical trials and accelerate development of new AA treatments.
The European Hematology Association (EHA) collaborates with researchers to develop standardized treatment guidelines and improve care for AA patients across Europe.
List of Acquired Aplastic Anemia Key Companies in the Market
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)